OSE Immunotherapeutics — Tedopi shows promise in pancreatic cancer
OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with...
111 Views
OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with...
397 Views
OSE Immunotherapeutics - Riding the H124 tailwinds
OSE Immunotherapeutics has reported its results for H124, a standout period for the company’s development pipeline, with the momentum carrying into...
306 Views
OSE Immunotherapeutics - Tedopi registrational study commences
OSE Immunotherapeutics has announced the initiation of its Phase III registrational study (Artemia) for lead cancer vaccine Tedopi, with the trial...
462 Views
OSE Immunotherapeutics - Lusvertikimab shines in Phase II UC trial
OSE Immunotherapeutics’ run of positive news continues with the announcement of encouraging data from the Phase II proof-of-concept CoTikiS study,...
394 Views